


1/9


Figure 1

Possible Modifications/ Attributes of Tezepelumab



CDR# and FR#	Motif	Predicted Modification
CDR H1	M34	Oxidation
CDR H2	W52	Oxidation
CDR H2	D54	Isomerization
CDR H2	N57	Deamidation
CDR H2	D62	Isomerization
CDR H3	W102	Oxidation
FR L1	N25	Deamidation
FR L1	N26	Deamidation
CDR L2	D49D50	Isomerization
CDR L2	D52	Isomerization
FR L2	N65	Deamidation
CDR L3	W90	Oxidation
CDR L3	D91	Isomerization
CDR L3	S92S93S94	Mannosilation
CDR L3	D95	Isomerization




2/9

Figure 2


3/9

Figure 3A and Figure 3B**FIG. 3A****FIG. 3B**


4/9

Figure 4

5/9

Figure 5A and Figure 5B

6/9

Figure 6

7/9

Figure 7A and Figure 7B




Figure 8A

Sample ID/Description	% Isomerization			% Relative Potency (%CV)	
	D54 HC	D49/50 LC	D91/95 LC	Receptor-ligand Binding	Cell-based Reporter Gene Bioassay
AMG 157 Drug Substance	0.0	0.2	0.0	102	102
Stressed AMG 157 Sample (4week@40C)	1.8	5.4	0.3	104	91

Figure 8B




Figure 8C

Sample ID/Description	% Isomerization			% Relative Potency (%CV)	
	D54 HC	D49/50 LC	D91/95 LC	Receptor-ligand Binding	Cell-based Reporter Gene Bioassay
Control	0.0	0.2	0.0	102	102
Stressed Sample (4week@40C)	1.8	5.4	0.3	104	91
Stressed Sample Basic Fraction 1	0.1	12	0.1	101%(11%)	94%(3%)
Stressed Sample Basic Fraction 2	0.6	8.3	0.1	83%(8%)	86%(5%)
Stressed Sample Basic Fraction 3	39.2	1.6	0	78%(8%)	59%(7%)
Stressed Sample Basic Fraction 4	Too low to be tested by peptide mapping			59%(9%)	15%(13%)

Figure 8D

Modification	Reference Standard	Vial drug product lot A, 12M 5°C	Vial drug product lot B, 12M 5°C	Bench Scale DP T=0	Bench Scale DP, 18M 5°C	Bench Scale DP, 6M 25°C	DS Stability 22M 5°C 2M 30°C
Asp Isomerization (LC CDR, D49/D50)	0.2%	2.2%	2.7%	0.6%	3.7%	6.9%	9.1%
Asp Isomerization (HC CDR, D54)	0.0%	0.1%	0.1%	0.0%	0.1%	0.6%	1.4%